- GBI & PARTNERS
- Fluidigm turns to China's Puluoting to promote CyTOF
Fluidigm turns to China's Puluoting to promote CyTOF
China’s Zhejiang Puluoting Health Technology Co., Ltd (PLTTECH) struck a licensing deal with US-based Fluidigm Corporation (NSDQ:FLDM). The two will advance the sales and application of the latter’s cytometry by time of flight (CyTOF) technology, as well as mass spectrometry flow panel and reagents in the clinical laboratory market in China, where clinical diagnostic filing for the CyTOF platform will be made. PLTTECH plans to acquire three CyTOF systems within 2 years to develop a blood cancer diagnosis panel (especially blood cancer in children) and immunotherapy prognosis panel. No financial details were disclosed.
Fluidigm acquired its CyTOF capabilities via the acquisition of DVS Sciences in 2014 to become a reference company in single cell technology. The firm's products can be used to provide clinical translational research support in the fields of cancer and immunotherapy, including identifying biomarkers. Fluidigm sells a variety of commonly used metal-antibody conjugates, and an antibody conjugation kit and has a global business presence.
PLTTECH is also focused on single cell precision research, utilizing world-class CyTOF technology and a biological information analysis platform to provide precision medicine and health management solutions through extensive collaboration in medical research, clinical diagnosis and treatment, drug development, and more.
- Argentina,Brazil,Colombia,Chile,Puerto Rico ,Costa Rica,Panama,Peru,Paraguay,Uruguay,Ecuador ,Bolivia ,Mexico,Guatemala,Honduras,El Salvador,Belize,Nicaragua